Journal of Substance Abuse Treatment
Volume 34, Issue 2 , Pages 192-201 , March 2008

Individual and system influences on waiting time for substance abuse treatment

  • Carey J.A. Carr, M.P.H.

      Affiliations

    • Center for Interventions, Treatment, and Addictions Research (CITAR), Boonshoft School of Medicine, Wright State University, Dayton, OH 45435, USA
    • ,
  • Jiangmin Xu, Ph.D.

      Affiliations

    • Center for Interventions, Treatment, and Addictions Research (CITAR), Boonshoft School of Medicine, Wright State University, Dayton, OH 45435, USA
    • ,
  • Cristina Redko, Ph.D.

      Affiliations

    • Center for Interventions, Treatment, and Addictions Research (CITAR), Boonshoft School of Medicine, Wright State University, Dayton, OH 45435, USA
    • ,
  • D. Timothy Lane, M.Ed.

      Affiliations

    • Center for Interventions, Treatment, and Addictions Research (CITAR), Boonshoft School of Medicine, Wright State University, Dayton, OH 45435, USA
    • ,
  • Richard C. Rapp, M.S.W.

      Affiliations

    • Center for Interventions, Treatment, and Addictions Research (CITAR), Boonshoft School of Medicine, Wright State University, Dayton, OH 45435, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 937 775 3856; fax: +1 937 775 3395.
    • ,
  • John Goris, M.S.

      Affiliations

    • Samaritan Behavioral Health, Elizabeth Place, Dayton, OH 45408, USA
    • ,
  • Robert G. Carlson, Ph.D.

      Affiliations

    • Center for Interventions, Treatment, and Addictions Research (CITAR), Boonshoft School of Medicine, Wright State University, Dayton, OH 45435, USA

Received 10 January 2007 ,Revised 22 February 2007 ,Accepted 4 March 2007.

References 

  1. Adamson AJ, Sellman JD. The pattern of intravenous drug use and associated criminal activity in patients on a methadone treatment waiting list. Drug and Alcohol Review. 1998;17:159–166
  2. Addenbrooke WM, Rathod NH. Relationship between waiting time and retention in treatment amongst substance abusers. Drug and Alcohol Dependence. 1990;26:255–264
  3. Alexander JA, Nahra TA, Wheeler JRC. Managed care and access to substance abuse treatment services. Journal of Behavioral Health Services & Research. 2003;30:161–175
  4. American Psychiatric Association . Diagnostic and statistical manual of mental disorders—IV-TR. 4th ed.. Washington, DC: American Psychiatric Association; 2000;
  5. American Society of Addiction Medicine . Patient placement criteria for the treatment for substance-related disorders. 2nd ed.. Chevy Chase, MD: American Society of Addiction Medicine; 2001;
  6. Appel PW, Ellison AA, Jansky HK, Oldak R. Barriers to enrollment in drug abuse treatment and suggestions for reducing them: Opinions of drug injecting street outreach clients and other system stakeholders. American Journal of Drug and Alcohol Abuse. 2004;30:129–153
  7. Bell J, Caplehorn JRM, McNeil DR. The effect of intake procedures on performance in methadone maintenance. Addiction. 1994;89:463–471
  8. Best D, Noble A, Ridge G, Gossop M, Farrell M, Strang J. The relative impact of waiting time and treatment entry on drug and alcohol abuse. Addiction Biology. 2002;7:67–74
  9. Brown BS, Hickey JE, Chung AS, Craig RD, Jaffe JH. The functioning of individuals on a drug abuse treatment waiting list. American Journal of Drug and Alcohol Abuse. 1989;1:261–274
  10. Carlson RG. Ethnography and applied substance misuse research: Anthropological and cross-cultural factors. In:  Miller W,  Carroll K editor. A rethinking of substance abuse: What the science shows, and what we should do about it. New York: Guilford; 2006;p. 201–219
  11. Chawdhary A, Sayre SL, Green C, Schmitz JM, Grabowski J, Mooney ME. Moderators of delay tolerance in treatment-seeking cocaine users. Addictive Behaviors. 2007;32:370–376
  12. Claus RE, Kindleberger LR. Engaging substance abusers after centralized assessment: Predictors of treatment entry and dropout. Journal of Psychoactive Drugs. 2002;34:25–31
  13. Donovan DM, Rosengren DB, Downey L, Cox GB, Sloan KL. Attrition prevention with individuals awaiting publicly funded drug treatment. Addiction. 2001;96:1149–1160
  14. Downey L, Rosengren DB, Donovan DM. Gender, waitlists, and outcomes for public-sector drug treatment. Journal of Substance Abuse Treatment. 2003;25:19–28
  15. Ettner SL, Huang D, Evans E, Ash DR, Hardy M, Jourabchi M. Benefit–cost in the California Treatment Outcome Project: Does substance abuse treatment “pay for itself”?. Health Services Research. 2006;41:192–213
  16. Farabee D, Leukefeld CG, Hays L. Accessing drug-abuse treatment: Perceptions of out of treatment injectors. Journal of Drug Issues. 1998;28:381–394
  17. Festinger DS, Lamb RJ, Kountz MR, Kirby KC, Marlowe D. Pretreatment dropout as a function of treatment delay and client variables. Addictive Behaviors. 1995;20:111–115
  18. French MT. Brief Drug Abuse Treatment Cost Analysis Program (Brief DATCAP): Program version. 1st ed.. Coral Gables, FL: University of Miami; 2002;
  19. French MT, Dunlap LJ, Zarkin GA, McGeary KA, McLellan AT. A structured instrument for estimating the economic cost of drug abuse treatment: The Drug Abuse Treatment Cost Analysis Program (DATCAP). Journal of Substance Abuse Treatment. 1997;14:445–455
  20. Friedmann PD, Lemon SC, Stein MD, D'Aunno TA. Accessibility of addiction treatment: Results from a national survey of outpatient substance abuse treatment organizations. Health Services Research. 2003;38:887–903
  21. Gardner LI, Metsch LR, Anderson-Mahoney P, Loughlin AM, del Rio C, Strathdee S, et al. Efficacy of a brief case management intervention to link recently diagnosed HIV-infected persons to care. AIDS. 2005;19:423–431
  22. Heather N. Motivational interviewing: Is it all our clients need?. Addiction Research & Theory. 2005;13:1–18
  23. Hser Y, Maglione M, Polinsky ML, Anglin MD. Predicting drug treatment entry among treatment-seeking individuals. Journal of Substance Abuse Treatment. 1998;15:213–220
  24. Hubbard RL, Craddock SG, Anderson J. Overview of 5-year follow-up outcomes in the Drug Abuse Treatment Outcome Studies (DATOS). Journal of Substance Abuse Treatment. 2003;25:125–134
  25. Hunkeler EM, Hung Y, Rice DP, Weisner C, Hu T. Alcohol consumption patterns and health care costs in an HMO. Drug and Alcohol Dependence. 2001;64:181–190
  26. Kaplan EH, Johri M. Treatment on demand: An operational model. Health Care Management Science. 2000;3:171–183
  27. Koenig L, Siegel JM, Harwood H, Gilani J, Chen YJ, Leahy P, et al. Economic benefits of substance abuse treatment: Findings from Cuyahoga County, Ohio. Journal of Substance Abuse Treatment. 2005;28:S41–S50
  28. McCaughrin WC, Howard DL. Variation in access to outpatient substance abuse treatment: Organizational factors and conceptual issues. Journal of Substance Abuse. 1996;8:403–415
  29. McCollister KE, French MT. The relative contribution of outcome domains in the total economic benefit of addiction interventions: A review of first findings. Addiction. 2003;98:1647–1659
  30. McLellan AT. The fifth edition of the Addiction Severity Index. Journal of Substance Abuse Treatment. 1992;9:199–213
  31. Palepu A, Tyndall MW, Leon H, Muller J, O'Shaughnessy MV, Schechter MT, et al. Hospital utilization and cost in a cohort of injection drug users. Canadian Medical Association. 2001;165:415–420
  32. Pollini RA, McCall L, Mehta SH, Vlahov D, Strathdee SA. Non-fatal overdose and subsequent drug treatment among injection drug users. Drug and Alcohol Dependence. 2006;83:104–110
  33. Rapp RC. Strengths-based case management: Enhancing treatment for persons with substance abuse problems. In:  Saleebey D editors. The strength perspective in social work practice. Boston, MA: Allyn and Bacon; 2006;p. 124–142
  34. Rapp RC, Siegal HA, Li L, Saha P. Predicting postprimary treatment services and drug use outcome: A multivariate analysis. American Journal of Drug and Alcohol Abuse. 1998;24:603–615
  35. Rapp, R. C., Xu, J., Carr, C. A., Lane, T., Redko, C., Wang, J., et al. (in press). Understanding treatment readiness in recently assessed, pre-treatment substance abusers. Substance Abuse.
  36. Rapp RC, Xu J, Carr CA, Lane T, Wang J, Carlson RG. Treatment barriers identified by substance abusers assessed at a centralized intake unit. Journal of Substance Abuse Treatment. 2006;30:227–235
  37. Redko C, Rapp RC, Carlson RG. Waiting time as a barrier to treatment entry: Perceptions of substance abusers. Journal of Drug Issues. 2006;4:831–852
  38. Rotstein DL, Alter DA. Where does the waiting list begin? A short review of the dynamics and organization of modern waiting lists. Social Science & Medicine. 2006;62:3157–3160
  39. SAS Institute . SAS/STAT user's guide. Version 8. Cary, NC: SAS Institute; 1999;
  40. Schottenfeld RS, O'Malley S, Abdul-Salaam K, O'Connor P. Decline in intravenous drug use among treatment-seeking opiate users. Journal of Substance Abuse Treatment. 1993;10:5–10
  41. Schwartz RP, Highfield DA, Jaffe JH, Brady JV, Butler CB, Rouse CO, et al. A randomized controlled trial of interim methadone maintenance. Archives of General Psychiatry. 2006;63:102–109
  42. Siegal HA, Rapp RC, Kelliher CW, Fisher JH, Wagner JH, Cole PA. The strengths perspective of case management: A promising inpatient substance abuse treatment enhancement. Journal of Psychoactive Drugs. 1995;27:67–72
  43. Simpson D, Joe G, Brown B. Treatment retention and follow-up outcomes in the Drug Abuse Treatment Outcome Study (DATOS). Psychology of Addictive Behavior. 1997;11:294–307
  44. Stark MJ, Campbell BK, Brinkerhoff CV. “Hello, may we help you?” A study of attrition prevention at the time of the first phone contact with substance-abusing clients. American Journal of Drug and Alcohol Abuse. 1990;16:67–76
  45. Wenger LD, Rosenbaum M. Drug treatment on demand—Not. Journal of Psychoactive Drugs. 1994;26:1–11
  46. Xu, J., Wang, J., Rapp, R. C., & Carlson, R. G. (in press). The multidimensional structure of internal barriers to substance abuse treatment and its invariance across gender, ethnicity, and age. Journal of Drug Issues.
  47. Zarkin GA, Dunlap LJ, Hicks KA, Mamo D. Benefits and costs of methadone treatment: Results from a lifetime simulation model. Health Economics. 2005;14:1133–1150

PII: S0740-5472(07)00088-8

doi: 10.1016/j.jsat.2007.03.005

Journal of Substance Abuse Treatment
Volume 34, Issue 2 , Pages 192-201 , March 2008

Article Tools